嵌合抗原受体修饰T细胞治疗恶性淋巴瘤研究进展  

Research progress of chimeric antigen receptor modified T cells in malignant lymphoma

作　　者：蒋婷[1] 纪青[1] 邓飞[1] 

机构地区：[1]遵义医学院病理学教研室,贵州遵义563000

出　　处：《海南医学》2017年第4期612-614,共3页Hainan Medical Journal

基　　金：国家自然科学基金(编号:81160300)

摘　　要：恶性淋巴瘤(ML)是起源于淋巴造血系统的恶性肿瘤,现有的常规治疗手段主要为化疗和放疗,但不良反应较大,疗效欠佳。嵌合抗原受体修饰T细胞(CAR-T)疗法是近年来治疗恶性肿瘤的一种新模式,在淋巴造血系统肿瘤治疗上显示了良好的抗肿瘤效应,但CAR-T细胞也会杀伤带有CAR相对应抗原的正常细胞,产生细胞因子风暴等副作用。本文从CAR原理及结构及其在ML中的临床应用和不良反应等方面作简要综述。Malignant lymphoma （ML） is a malignant tumor originating in the lymphoid hematopoietic system. Current conventional treatment methods to ML are mainly chemotherapy and radiotherapy, but they both cause many ad- verse reactions, and the therapeutic efficacy is unsatisfactory. The modified chimeric antigen receptor T cells （CAR-T） therapy is a kind of new pattern of malignant tumor therapy in recent years. It shows great effect on lymphatic hemato- poietic system, but CAR-T cells will also kill the normal cells that wearing CAR antigen, which can cause cytokine storm and other risks. In this review, CAR principle and its structure, and its clinical use and existing problems in malig- nant lymphoma treatment are summarized.

关 键 词：嵌合抗原受体 T细胞 恶性淋巴瘤 进展 

分 类 号：R733.4[医药卫生—肿瘤]